BACKGROUND: Serum concentrations of ST2 (interleukin-1 receptorlike 1) represent a meaningful prognostic marker in cardiac diseases. Production of soluble ST2 (sST2) may be partially extracardiac. Identification of sST2 sources is relevant to design strategies for modulating its signaling.
S
T2 (interleukin-1 receptor-like 1) is a member of the IL (interleukin)-1 receptor family with 2 main isoforms: transmembrane or cellular (ST2L) and a circulating, soluble form (soluble ST2 [sST2]). 1 (Note that in this article ST2 refers only to interleukin-1 receptor-like 1, not suppression of tumorigenicity-2.) The interaction between ST2L and its ligand IL-33 has been demonstrated to be cardioprotective in experimental models, resulting in prevention of myocardial fibrosis, hypertrophy, and apoptosis. 2 However, sST2 avidly binds IL-33, which results in interruption of the interaction between IL-33/ ST2L; thus, sST2 is viewed as a decoy receptor, preventing transduction of favorable effects of IL-33 through ST2L. Circulating concentrations of sST2 are elevated in peripheral blood of patients with acute myocardial infarction (AMI) and heart failure (HF). 3, 4 In the setting of AMI, sST2 concentrations increase from the first day, correlate with the degree of necrosis and ventricular systolic dysfunction, and are associated with an increased risk of death and HF in the follow-up. 5 The prognostic information provided by circulating sST2 concentrations is additive over other clinical variables and biomarkers, including natriuretic peptides, with similar additive prognostic value in HF. 3, 4, 6 Together, these results indicate sST2 is of pathophysiological importance in cardiac diseases.
Although cardiac fibroblasts and cardiomyocytes are molecular sources of sST2 in response to stress or injury, emerging data suggest a disconnection between tissuebased ST2 expression and circulating concentrations; relatively little is known about extracardiac production and regulation of sST2. [1] [2] [3] It is established endothelial cells from both macrovascular (aortic and coronary) and cardiac microvascular system may release sST2. 7, 8 Vascular production of sST2 in other organs remains speculative, however. We and others have noticed close relation between sST2 circulating levels and pulmonary diseases 9 ; some of the highest concentrations of sST2 in clinical studies have been recorded in patients with acute respiratory distress syndrome. 10 Thus, production of sST2 in lung tissue may explain circulating concentrations of the biomarker. The present study aimed to evaluate whether lungs are a significant source of sST2 in the context of HF.
METHODS
For a more detailed description of methodology, see the expanded Methods in the Data Supplement. The data, analytic methods, and study materials that support the findings of this study are available from the corresponding author on reasonable request.
Experimental Protocol
All experimental protocols were approved by the University of Murcia Committee on the Ethics of Animal Experiments (permit number: A13150105).
Male Wistar rats were purchased at 6 weeks of age and housed under standard laboratory conditions in a pathogenfree facility with controlled rooms and 12-hour light/dark cycle, at 22°C and 60% humidity, and fed ad libitum. After 7 days of adaptation, the animals were randomly split into experimental groups for induction of AMI, as described previously. 11 A detailed description of the surgical and echocardiography procedures is included in the Data Supplement. Briefly, AMI was induced by permanent ligation of the left anterior descending coronary artery. Infarcted rats were randomly assigned to 4 groups according to the time assigned from surgery to the euthanization: 1, 2, 4, and 24 weeks. Sham-operated animals underwent the same surgical procedures, without coronary artery ligation. Mortality within the first 24 hours after the induction of AMI was 26% in infarcted animals, and no deaths occurred after 24 hours post-infarction. At each time, rats were euthanized, and their organs (lung, heart, kidney, and liver) were carefully removed. A transverse section of each organ was formalin fixed and paraffin wax embedded for immunohistochemical examination. The rest of each organ was immediately frozen in liquid nitrogen and stored at −80°C for gene expression determination. Transthoracic echocardiography was performed at the day of euthanization by a single experienced operator in a blinded fashion, as described previously.
11

Quantitative reverse transcription polymerase chain reaction
The mRNA from 30 mg of each tissue was isolated using the Dynabeads mRNA Direct Kit (Amersham Pharmacia Biotech, Piscataway, NJ), and cDNA was synthesized using GeneAmp RNA PCR Kit (Roche, Branchburg, NJ), according to the manufacturer's instructions. The reverse transcription polymerase chain reaction was performed with SYBR Premix Ex Taq (Takara Biotechnology, Dalian, China) in a LightCycler system (Roche). The genes amplified were IL-33, sST2, ST2L, and GAPDH, the last one as housekeeping gene. Efficiency for each primer pair was assessed, and 0.5 μL of template cDNA was amplified by 40 cycles of reverse transcription polymerase chain reaction (10 seconds at 95°C, 10 seconds at 60°C, and 15 seconds at 72°C). Data were normalized to GAPDH expression and are presented as fold relative to the sham group. The primer sequences were described previously.
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WHAT IS NEW?
• In an experimental model of heart failure, soluble ST2 (interleukin-1 receptor-like 1) is upregulated in lungs and secreted by pneumocytes in response to strain.
• In patients with cardiogenic pulmonary edema, soluble ST2 is present at high concentrations in bronchial aspirates.
• The lungs emerge as a relevant source of soluble ST2 in the presence of heart failure.
WHAT ARE THE CLINICAL IMPLICATIONS?
• These results may have implications for the understanding of ST2 system in heart failure and for the development of new therapies targeted to ST2.
Immunohistochemistry
Formalin-fixed and paraffin-embedded lung tissues were sectioned (3 μm) and placed on poly-L-lysine-coated glass slides. The sections were deparaffinized and pretreated in Dako PT Link for 20 minutes to 97°C using EnVision FLEX Target Retrieval Solution, High pH (Dako, Denmark). For sST2 staining, rehydrated sections were incubated overnight with polyclonal antibody to sST2 (working dilution 1:500; Proteintech, Chicago, IL). After primary antibody, sections were then incubated with an anti-rabbit biotinylated-labeled polymer (Dako EnVision,) according to manufacturer's protocols. Sections were finally revealed with 2,2′-diaminobencidine. Positive immunostaining was identified as a cytoplasmic dark-brown precipitate. High-resolution images were obtained through a Zeiss Axio Scope A10 (Carl Zeiss, Madrid, Spain) microscope.
Isolation and Purification of Alveolar Epithelial Type II Cells From Human Lungs
The method of isolation was established by adaption and modification of several previous protocols. 13, 14 Flow cytometry and sorting of lung component cells was used for subsequent purification. A detailed description of the isolation and purification procedures is included in the Data Supplement.
Biochemical Strain Simulation Model
Isolated human primary cells were cultured in complete medium. To induce biochemical strain, cells were made quiescent before any treatment by decreasing of fetal bovine serum at 0.1% and then costimulated with 0.2 μM phorbol-12-myristate-13-acetate and 0.4 μM A23187 for 10 or 24 hours, which induce a cell stretch sustained over time. 15 Several studies have described that these molecules are often used in conjunction to induce a strong hypertrophic cell growth response when applied in vitro 15 and have previously been shown to stimulate synthesis and sST2 secretion.
Clinical Study
Twenty-nine patients (61% men; 63±16 years) admitted to an intensive care unit requiring invasive ventilatory support were prospectively recruited; diagnoses in these patients included the following pathogeneses: acute cardiogenic pulmonary edema (without pulmonary disease), bronchopneumonia (without cardiac disease), and brain disorders (without pulmonary or cardiac diseases). In all cases, an echocardiography was performed to confirm or rule out the presence of cardiac dysfunction. Consensus agreement between 2 different physicians was necessary to confirm the final diagnosis for each patient. At the time of intubation, samples of bronchial aspirate were taken by insertion of a cannula into the major bronchus, and at the same time, blood samples were taken from a central vein. The bronchial aspirates were homogenized by brief sonication on ice (2×30 seconds; Sonopuls HD 2200; Bandelin, Berlin, Germany) followed by centrifugation at 13 000 rpm for 10 minutes. Aspirate and serum samples were stored at −80°C until analysis. Clinical variables were prospectively recorded at the time of intubation and thereafter. The concentrations of sST2 in aspirate and serum samples were measured using the human Presage ST2 Assay (Critical Diagnostics, CA) per the instructions provided by the manufacturer. Each sample was measured in duplicate.
Statistical Analysis
Data were expressed as mean±SE of mean or SD as stated. Normality was tested using Kolmogorov-Smirnov test. An unpaired t test or Mann-Whitney U test was used for comparisons between 2 groups, as appropriate. A 1-way ANOVA or the Kruskal-Wallis test was used for multiple comparisons between the AMI groups and the sham group, whereas post hoc analyses were used with the sham group as control. Nonparametric correlations were studied by using Spearman method. Statistical significance was assumed at P<0.05. Data were statistically analyzed using SPSS statistics 22 (IBM Corp)
RESULTS
Extracardiac Expression of sST2 in the Model of Ischemic HF
After AMI and development of HF, rats with experimental AMI showed increase in heart, liver, and lung weight, compared with the sham group. Echocardiographic examination, performed immediately before the euthanization, showed adverse cardiac remodeling and left ventricular systolic dysfunction in the infarcted rats as compared with sham group. The descriptive analysis is shown in Table I in the Data Supplement.
The mRNA expression level of IL-33, sST2, and ST2L was evaluated by quantitative reverse transcription polymerase chain reaction in heart, lung, kidney, and liver ( Figure 1 ). In the lungs (panel A), mRNA expression of sST2 was significantly higher during the first week after AMI (P=0.004) and remained steady until 24 weeks after MI; in contrast, mRNA expression of IL-33 and ST2L in lungs decreased acutely at 1 week after AMI and returned to sham levels after 4 weeks. In myocardium (panel B), the mRNA expression of all related molecules (sST2, ST2L, and IL-33) was increased. Therefore, ST2L/IL-33 exhibited a different pattern in response to AMI between lungs (decrease) and myocardium (increase). These results were confirmed in the protein analysis (Results in the Data Supplement; Figure  I in the Data Supplement). Accordingly, sST2 expression correlated with ST2L in an opposite way in lung and heart: inversely in lungs (ρ=−0.58; P<0.001) and positively in heart (ρ=0.59; P<0.001). ST2L response correlated strongly with IL-33 response in either heart (ρ=0.77; P<0.001) or lung (ρ=0.93; P<0.001). By contrast to lungs and heart, no significant changes or correlations were found in kidney and liver (Figure 1 
Inmunohistochemical Expression of sST2 in Lung Tissue
Histopathology examination of lung tissue (Figure 2A ) revealed reduction of alveolar spaces with increased parenchymal edema and alveolar wall thickening, compared with sham group ( Figure II in the Data Supplement). These pathological changes were prominent at 1 week and persisted out to 24 weeks from AMI. Similarly, sST2 protein was detected intensely in the alveolar epithelium at 1 week and remained visible after 24 weeks from AMI ( Figure 2B ). We found a positive correlation between alveolar wall thickness and sST2 protein at 1 and 24 weeks (ρ=0.83, P<0.001; ρ=0.89, P<0.001, respectively; Figure 2C ). As shown in Figure 3 , sST2 inmunoexpression was intensely detected in the epithelial alveolar pneumocytes at 1 week and persisted after 24 weeks (panels A through C, red asterisks). Additionally, weak sST2 expression was observed in a small population of parenchymal-positive macrophages (green arrows). Additional representative and detailed images of alveolar epithelium and parenchymal polymorphonuclear neutrophils are included as Figure III 
Type II Human Pneumocytes Expressed sST2 Under Strain
We obtained primary human type II pneumocyte cells fractions, and its purity was confirmed in additional experiments ( Figure IV in the Data Supplement). To test whether type II human pneumocytes are involved in the production of sST2 isoform, we used an experimental model of biomechanical strain and hypertrophy by costimulation with phorbol-12-myristate-13-acetate and A23187. A significant increase in sST2 mRNA expression ( Figure 4A ) was observed after 10 and 24 hours of biochemical strain, compared with control (P<0.001). Similar results were obtained when we evaluated the sST2 release into the cellular supernatant ( Figure 4B ). The expression levels of sST2 correlated positively with those of pulmonary surfactant protein type-B (ρ=0.84; P<0.001; Figure 4C )-a marker of alveolar and pneumocyte damage.
sST2 in Bronchial Aspirate
Bronchial aspirates and serum were obtained at the time of endotracheal intubation in patients with acute pulmonary cardiogenic edema (n=12), severe broncho- -1 receptor-like 1) . A, Quantitative reverse transcription polymerase chain reaction analysis of mRNA levels of sST2. B, sST2 protein levels in cellular supernatant. C, Correlation data between SP-B (surfactant protein B) vs sST2 levels. A indicates calcium ionophore A23187; and PMA, phorbol-12-myristate-13-acetate. ***P<0.001 vs control group. pneumonia (n=9), and neurological disorders (n=8). sST2 was measured in serum at a median concentration of 297 (interquartile range [IQR], 119-342) ng/mL and in bronchial aspirates at a median concentration of 7.0 (IQR, 2.9-128.8) ng/mL; a modest significant correlation between concentrations in both locations was found (ρ=0.50; P=0.006). Figure 5 shows the concentrations of sST2 in lung aspirate (panel A) and serum (panel B) according to pathogeneses. Serum sST2 concentrations did not differ between patients with acute HF and noncardiac causes; however, sST2 concentrations in lung aspirates were substantially higher in the presence of cardiogenic pulmonary edema (n=12; median, 228; [IQR, 28.4-324.0] ng/mL) than bronchopneumonia (n=9; median, 5.5 [IQR, 1.6-6.5] ng/mL; P<0.001) or neurological disorders (n=8; median, 2.9 [IQR, 1.7-10.1] ng/mL; P<0.001). sST2 concentration in the bronchial aspirate correlated with serum levels of sST2 (ρ=0.71; P=0.008) and cardiac (left ventricular ejection fraction, natriuretic peptides, and troponin T), hemodynamic (systolic blood pressure), and metabolic measures (lactate and lactate dehydrogenase; Table II in the Data Supplement).
DISCUSSION
We sought to examine the question of whether the lungs represent a meaningful source of sST2 production in cardiac diseases. We found in an experimental model of AMI and ischemic HF, substantial and sustained pulmonary production of sST2, where alveolar epithelial cells represented a relevant source in response to mechanical stress. The relevance of lungs in production of sST2 in cardiac diseases was then confirmed in the bronchial aspirate obtained from patients with pulmonary cardiogenic edema.
The presence of high concentrations of sST2 in the circulation identifies a worse prognosis in cardiac diseases. 3, 4 Intact and normally functioning ST2L/IL-33 signaling has been described in the cardiomyocyte as biomechanically induced and cardioprotective, 3 whereas the soluble, circulating form of ST2 has been identified as a decoy receptor of IL-33 able to abrogate the protective action of the binding ST2L/IL-33. In this scenario, the source of sST2 in cardiovascular diseases has not been clarified, but a relevant extracardiac production has been suggested by several, including our, groups. 7, 8, [16] [17] [18] Although myocardial expression of sST2 is well documented, a link to circulating concentrations is more elusive. Bartunek et al 7 were the first to suggest nonmyocardial production of sST2 protein, and then Demyanets et al 8 have also proposed endothelia as a main source of ST2 protein. Invasive studies involving coronary sinus sampling have not demonstrated a transcardiac gradient of sST2. 7, 18, 19 Extracardiac production is also supported by the physiological role of ST2 as a mediator of inflammation and immunity in several diseases. Indeed, sST2 modulates IL-33 activity during inflammatory responses, and both are elevated in patients with exacerbations of allergic and autoimmune diseases. In a mouse asthma model, sST2 was produced predominantly in lung and leukocytes, 20 and, in mice with anaphylaxis, sST2 was released by mast cells, both peripheral blood derived and bone marrow derived. 21 In addition, circulatory sST2 is strongly enhanced in other inflammation-associated illnesses, as sepsis, trauma, stroke, or chronic obstructive pulmonary disease. [22] [23] [24] [25] [26] In the present work, we first used an animal model of ischemic HF after AMI. In this experimental model, we have previously shown that IL-33 and sST2 were upregulated in the infarcted myocardium during the first week after AMI. 11, 12 We presently found liver and kidney did not exhibit sST2 expression, but the lungs showed early and intense increase of sST2 in terms of both RNA levels and protein expression. Our findings are in accordance with Chen et al, 17 who found mRNA levels of sST2 were the greatest in the lungs among vital organs from mice with transverse aortic constriction. These results are also in agreement with Mildner et al, 16 who analyzed pooled organ-specific cDNAs and found the highest sST2 expression in alveolar and bronchus epithelia and proposed lung tissue as a main source of sST2. Our data extend these observations to the more relevant disease state of AMI and HF, where sST2 testing is more commonly applied; we also show alveolar epithelia as a main source of sST2.
Interestingly, we found an association between the increase in alveolus thickness and the upregulation of sST2, which suggests a relationship between severity of pulmonary edema and sST2 production. These findings suggest that sST2 may increase in the lung as a consequence of alveolar strain after pulmonary edema. To provide further support for this argument, we used an experimental model of strain by costimulation with the phorbol ester phorbol-12-myristate-13-acetate and the ionophore A23187, which induce a cell stretch sustained over time. 15 In this model of pneumocyte stress, we found increasing ST2 mRNA expression accompanied by increasing sST2 concentration in the cellular supernatant. The increase in sST2 concentration was parallel to the SP-B (surfactant protein B)-a marker of damage to the alveolarcapillary barrier. Indeed, both showed a significant positive correlation when type II human pneumocytes were subjected to strain. These results strongly support alveolar epithelial cells as the source of sST2 production in cardiac diseases.
The coincident production of sST2 mRNA and protein together with lower mRNA expression of ST2L suggests elevated sST2 is an inducible response resulting from alternative splicing rather than proteolytic cleavage of ST2L in the lung. In addition, the inverse responses of IL-33/ST2L (down in lungs and up in myocardium) might suggest different regulations and adaptive local responses in alveolar epithelial cells (anti-inflammatory) and cardiomyocytes (cardioprotective). Among patients requiring ventilatory support in the setting of acute HF and noncardiac acute conditions (bronchopneumonia and stroke), we observed elevated serum concentrations of sST2 in agreement with the fact of circulating sST2 is elevated in a broad spectrum of acute diseases, 22 including lung infections 23, 24 sepsis and trauma 25 and stroke. 26 However, the presence of sST2 in the bronchial aspirate differed significantly depending on pathogenesis of disease: whereas patients with acute HF had high concentrations of bronchial aspirate sST2, those without cardiac disease did not. To our knowledge, there are no previous systematic reports of the presence of sST2 in bronchial fluid of patients with a range of cardiac and noncardiac disease. Although it could be hypothesized that sST2 concentrations in bronchial aspirates merely represent translocation of sST2 in pulmonary edema, our findings in the experimental models support an active role of this organ in ST2 production. The correlation between sST2 concentration in aspirates and hemodynamic, cardiac, and metabolic measures suggests that more severe congestion in the context of HF may result in induction of pulmonary ST2 expression. However, the low number of patients and the lack of direct measures of pulmonary pressures by right catheterization preclude definitive conclusions. The extent (if any) circulating sST2 produced in the lungs results in cardiovascular derangement remains unclear.
The present work is a hypothesis-generating study, given the role of lung in sST2 pathophysiology in cardiac disease has not been proposed previously (Figure 6) . The main limitation of the present work is that only associations were studied, and, therefore, causality cannot be established. Further studies are necessary to better understand how modulation of pulmonary ST2 expression might be leveraged as a potential therapeutic pathway in patients with HF.
In conclusion, the present study suggests that lungs are a relevant source of sST2 in HF and could play an active role in the pathophysiology of the ST2 response. Further studies are necessary to elucidate this response and its consequences.
